MARKET

EYPT

EYPT

EyePoint
NASDAQ
13.62
-0.36
-2.58%
Pre Market: 13.63 +0.01 +0.07% 04:57 05/13 EDT
OPEN
14.01
PREV CLOSE
13.98
HIGH
14.01
LOW
13.35
VOLUME
49
TURNOVER
0
52 WEEK HIGH
19.11
52 WEEK LOW
5.30
MARKET CAP
1.14B
P/E (TTM)
-3.8907
1D
5D
1M
3M
1Y
5Y
1D
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
TipRanks · 1d ago
Weekly Report: what happened at EYPT last week (0504-0508)?
Weekly Report · 2d ago
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
TipRanks · 5d ago
EyePoint Pharmaceuticals Price Target Cut to $37.00/Share From $39.00 by RBC Capital
Dow Jones · 5d ago
EyePoint Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 5d ago
RBC Capital Maintains Outperform on EyePoint, Lowers Price Target to $37
Benzinga · 5d ago
Ocular: SOL-1 Success Is Real, But Adoption Risks Keep Me At Hold
Seeking Alpha · 5d ago
RBC Capital Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)
TipRanks · 5d ago
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.